Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Movement Disorders

• Publication date

  2013-02-13

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1002/mds.25282PMID 23408705PMCID PMC3608817
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology

  2012cited by this paper
• Hippocampal and ventricular changes in Parkinson's disease mild cognitive impairment.

  2012cited by this paper
• White matter lesions in Parkinson disease

  2011influential reference
• Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease.

  2011cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid.

  2010cited by this paper
• In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia

  2010cited by this paper
• Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid

  2010influential reference
• The age‐related white matter changes scale correlates with cognitive impairment

  2010cited by this paper
• Ventricular maps in 804 ADNI subjects: correlations with CSF biomarkers and clinical decline.

  2010cited by this paper
• The progression of pathology in Parkinson's disease

  2010cited by this paper
• CSF Aβ42 and tau in Parkinson's disease with cognitive impairment

  2010influential reference
• CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease

  2010cited by this paper
• CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies

  2010cited by this paper
• 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects.

  2010cited by this paper
• CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study

  2010influential reference
• Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.

  2010cited by this paper
• Influence of White Matter Hyperintensities on the Cognition of Patients With Parkinson Disease

  2010influential reference
• Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.

  2010cited by this paper
• APOE Alleles in Parkinson Disease and Their Relationship to Cognitive Decline: A Population-based, Longitudinal Study

  2009cited by this paper
• Cerebrospinal tau, phospho‐tau, and beta‐amyloid and neuropsychological functions in Parkinson's disease

  2009cited by this paper
• Cognitive impairment in incident, untreated Parkinson disease

  2009cited by this paper
• Faculty Opinions recommendation of Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.

  2009cited by this paper
• Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly

  2009cited by this paper
• White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease

  2009influential reference
• CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

  2009cited by this paper
• Incidence of Parkinson’s disease in Norway: the Norwegian ParkWest study

  2009cited by this paper
• Neurochemical biomarkers in the differential diagnosis of movement disorders

  2009cited by this paper
• Trajectories of brain loss in aging and the development of cognitive impairment

  2008cited by this paper
• Automated ventricular mapping with multi-atlas fluid image alignment reveals genetic effects in Alzheimer's disease

  2008cited by this paper
• Automatic Subcortical Segmentation Using a Contextual Model

  2008cited by this paper
• Subtypes of mild cognitive impairment in parkinson's disease: Progression to dementia

  2006cited by this paper
• Visual rating of white matter hyperintensities in Parkinson's disease

  2006cited by this paper
• Apolipoprotein E ɛ4 allele is associated with the volume of white matter changes in patients with lacunar infarcts

  2006cited by this paper
• Alzheimer's disease

  2006cited by this paper
• Apolipoprotein E epsilon4 allele is associated with the volume of white matter changes in patients with lacunar infarcts.

  2006cited by this paper
• Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium

  2005cited by this paper
• Cognitive profile of patients with newly diagnosed Parkinson disease

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2005cited by this paper
• Mapping hippocampal and ventricular change in Alzheimer disease

  2004cited by this paper
• Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy

  2003cited by this paper
• Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy.

  2003cited by this paper
• Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis

  2002influential reference
• California Verbal Learning Test-Second Edition

  2002cited by this paper
• Studies of Interference in Serial Verbal Reactions

  2001cited by this paper
• Magnetic resonance image tissue classification using a partial volume model.

  2001cited by this paper
• [The Unified Parkinson's Disease Rating Scale].

  2000cited by this paper
• Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease

  2000cited by this paper
• Diagnostic criteria for Parkinson disease.

  1999cited by this paper
• Validation of the Warrington theory of visual processing and the Visual Object and Space Perception Battery.

  1998cited by this paper
• Automatic 3D Intersubject Registration of MR Volumetric Data in Standardized Talairach Space

  1994cited by this paper
• Studies of interference in serial verbal reactions.

  1992cited by this paper
• Regression Diagnostics — Identifying Influential Data and Sources of Collinearity

  1981cited by this paper
• Visuospatial Judgment: A Clinical Test

  1978cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper
• Parkinsonism

  1967cited by this paper

• The role of Apolipoprotein E4 on cognitive impairment in Parkinson’s disease and Parkinsonisms

  2025cites this paper
• CSF neurochemical profile and cognitive changes in Parkinson’s disease with mild cognitive impairment

  2023cites this paper
• Tau: a biomarker of Huntington’s disease

  2023cites this paper
• Serum miR-96-5P and miR-339-5P Are Potential Biomarkers for Multiple System Atrophy and Parkinson's Disease

  2021cites this paper
• Cognitive Impairment in Parkinson’s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors

  2021cites this paper
• A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies

  2020cites this paper
• An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele.

  2019cites this paper
• Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials

  2018cites this paper
• Aβ42/Aβ40 and Aβ42/Aβ38 Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimer’s Disease: A Pilot Study

  2018cites this paper
• A42/A40 and A42/A38 Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimer's Disease

  2018cites this paper
• Cognitive decline in Parkinson disease

  2017cites this paper
• Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease

  2017cites this paper
• Changes of cerebrospinal fluid Aβ42, t-tau, and p-tau in Parkinson’s disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis

  2017cites this paper
• Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease.

  2017cites this paper
• Impaired synaptic function is linked to cognition in Parkinson's disease

  2017cites this paper
• Hippocampal subfield atrophy in relation to cerebrospinal fluid biomarkers and cognition in early Parkinson’s disease: a cross-sectional study

  2016cites this paper
• Biomarkers for dementia and mild cognitive impairment in Parkinson's disease

  2016cites this paper
• Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders

  2016influential citation
• Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease

  2015cites this paper
• Understanding the Beneficial and Detrimental Effects of Donepezil and Rivastigmine to Improve their Therapeutic Value

  2015cites this paper
• Biomarkers of cognitive decline in Parkinson's disease.

  2015cites this paper
• Association of a BACE1 Gene Polymorphism with Parkinson's Disease in a Norwegian Population

  2015cites this paper
• Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease

  2014cites this paper
• Propagation of Oligomeric α-Synuclein and Amyloid-β: Implications for Parkinson's and Alzheimer's Diseases

  2014cites this paper
• Language-general and -specific white matter microstructural bases for reading

  2014cites this paper
• Mice Deficient in Transmembrane Prostatic Acid Phosphatase Display Increased GABAergic Transmission and Neurological Alterations

  2014cites this paper
• Human-Derived SOD 1 Antibodies Show Promise in ALS Mice

  2013cites this paper
• Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies

  2013cites this paper
• In vivo NMR studies of regional cerebral energetics in MPTP model of Parkinson's disease: recovery of cerebral metabolism with acute levodopa treatment

  2013cites this paper
• The more cortical amyloid‐β, the more postural instability in parkinson's disease: More grist to the mill for a link between walking, falling, and remembering?

  2013cites this paper